Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017

.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research

Related Links:

Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common condition of employment for health care workers (HCWs) to ensure compliance with national standards and state laws. When documentation of complete vaccination or laboratory-confirmed infection is not available, Advisory Committee on Immunization Practices (ACIP) criteria are used to guide vaccination or anti-MMRV IgG testing. We assessed the performance of the BioPlex 2200 MMRV IgG multiplex flow immunoassay (MFI; Bio-Rad Laboratories, Hercules, CA) and matched immunofluorescence assays (IFAs; MBL Bion, Des Plaines, IL) in 220 HCWs ca...
Source: Journal of Clinical Microbiology - Category: Microbiology Authors: Tags: Immunoassays Source Type: research
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
Progress toward rubella elimination has resulted in 168 (87%) of 194 countries protecting infants with rubella-containing vaccine and 81 (42%) eliminating rubella transmission.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety MMWR Morbidity & Mortality Weekly Report Vaccination Vaccines Source Type: news
Most commercially available enzyme immunoassay-based methods have limited sensitivity to detect antibody responses to varicella-zoster virus (VZV) in vaccinated individuals, who produce lower antibody levels than those with natural infection. However, more sensitive methods are either not commercially available or less amenable to high-throughput testing. The BioPlex 2200 measles, mumps, rubella, and varicella (MMRV) IgG assay (Bio-Rad Laboratories, Hercules, CA) is an automated high-throughput platform based on the microsphere Luminex technology that measures antibodies against measles, mumps, rubella, and varicella virus...
Source: Journal of Clinical Microbiology - Category: Microbiology Authors: Tags: Immunoassays Source Type: research
The percentage of adults aged ≥18 years who had lost all of their upper and lower natural teeth decreased from 9.3% in 2000 to 7.0% in 2017, and this pattern was consistent in each age group surveyed.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Breastfeeding Cancer Cancer Survivorship Hurricanes Infant Health Infection Measles Measles Vaccination Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety MMWR Mold Morbidity & Mortality Weekly Report Mosquito-Borne Disea Source Type: news
Estimated first-dose measles-containing vaccine (MCV) coverage increased from 57% to 76% during 2000-2017, and second-dose MCV coverage increased from 30% to 45% during 2009-2017.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Breastfeeding Cancer Cancer Survivorship Hurricanes Infant Health Infection Measles Measles Vaccination Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety MMWR Mold Morbidity & Mortality Weekly Report Mosquito-Borne Disea Source Type: news
On October 1, 2018, the Rockland County Department of Health alerted the New York State Department of Health of an unvaccinated teen traveler with diagnosed measles.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Active Communities Community Health Measles Measles Vaccination Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety MMWR Morbidity & Mortality Weekly Report Outbreaks Source Type: news
On December 31, 2018, Clark County Public Health in Washington was notified of a suspected case of measles in an unvaccinated child who had recently arrived from Ukraine.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Active Communities Community Health Measles Measles Vaccination Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Safety MMWR Morbidity & Mortality Weekly Report Outbreaks Source Type: news
CONCLUSION: The demonstration of batch consistency and non-inferiority of the Bio-MMR vaccine completed the technology transfer. This is a significant technological achievement with implications for immunisation programs. PMID: 30843921 [PubMed - in process]
Source: Memorias do Instituto Oswaldo Cruz - Category: Infectious Diseases Authors: Tags: Mem Inst Oswaldo Cruz Source Type: research
CONCLUSION: Demonstration of early disappearance of maternal antibodies against MMRV viruses leading to the risk of these infections at an early age emphasize need for early immunization of Indian children. Suboptimal response to measles vaccine needs to be seriously addressed especially in view of the WHO's initiative for measles eradication. PMID: 30765170 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
More News: Allergy & Immunology | Italy Health | Marketing | Measles | Measles Vaccine | MMR (Measles,Mumps,Rubella) Vaccine | Mumps | Mumps Vaccine | Rubella | Rubella Vaccine | Study | Vaccines